If a pharmaceutical company wished to design a drug to maintain low blood sugar levels, one approach might be to design a compound
A. that increases phosphodiesterase activity.
B. to stimulate G protein activity in liver cells.
C. that mimics epinephrine and can bind to the epinephrine receptor.
D. that stimulates cAMP production in liver cells.
E. that does any of the above.
Answer: A